journal article·2026-04Open access

Self-reinforcing nanoplatform uniting pemetrexed, magnetic hyperthermia and PD-L1 blockade reshapes the tumor microenvironment and elicits combined antitumor immunity in lung adenocarcinoma

Zhengjun Guo, Xulin Xie, Wenxiu Li, Shouhui Yi, Emmanuel Koomson, Renardi Gunawan, Zhihang Zhou, Md Kowsar Alam, Li Zhou, Tongxu Si, Zesheng Wang, Xiaoyu Zhou, Yuan Peng, Xiaoyue Zhang, Zhenzhou Yang, Mengsu Yang

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide, and immune checkpoint blockade is often limited by an immunosuppressive tumor microenvironment (TME). To address these challenges, we developed a novel multifunctional nanoplatform, based on a mesoporous Fe 3 O 4 core and silica shell, co-loading pemetrexed and an anti-PD-L1 antibody (PD-L1&Pem@msNPs). The construct enables checkpoint-targeted delivery, alternating magnetic field (AMF)-triggered hyperthermia and controlled drug release, enabling a single-system chemo–immuno–magnetothermal regimen. We comprehensively investigated the physicochemical properties, magnetothermal performance, loading/conjugation, and release behavior, and validated cellular uptake and cytotoxicity in vitro. In subcutaneous and orthotopic lung tumor models, PD-L1&Pem@msNPs achieved superior tumor suppression and extended survival compared with control formulations. Mechanistically, transcriptomic profiling together with immunophenotyping demonstrated marked TME remodeling, with increased intratumoral T-cell representation accompanied by coordinated rewiring of macrophages status. Notably, longitudinal flow cytometry revealed a shift in T-cell states from an exhausted-intermediate (Tex-int) toward a progenitor-like (Tex-prog) phenotype, consistent with restoration of T-cell functionality under treatment. Collectively, PD-L1&Pem@msNPs provides an externally activatable, modular platform to remodel the TME and improve the therapeutic impact of PD-L1 blockade in lung cancer. • Magnetothermal-chemo-PD-L1 platform enhances target release and immunogenicity. • Reverses the T cell exhaustion and remodels the immunosuppressive TME. • Tumor-targeted co-delivery achieves strong antitumor efficacy and limited toxicity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (44)

Show source-provided references
1. Cancer statistics
3. New promises and challenges in the treatment of advanced non-small-cell lung cancer10.1016/S0140-6736(24)01029-8 ↗
4. Toward personalized treatment approaches for non-small-cell lung cancer10.1038/s41591-021-01450-2 ↗
5. Lung cancer immunotherapy: progress, pitfalls, and promises10.1186/s12943-023-01740-y ↗
6. At the crossroads of immunotherapy for oncogene-addicted subsets of nsclc10.1038/s41571-022-00718-x ↗
7. Overcoming immunotherapy resistance in non-small cell lung cancer (Nsclc) - novel approaches and future outlook10.1186/s12943-020-01260-z ↗
8. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial10.1016/S1470-2045(20)30140-6 ↗
9. Updated analysis from keynote-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer10.1200/JCO.19.03136 ↗
10. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the sabr-comet phase ii randomized trial10.1200/JCO.20.00818 ↗
11. Pulmonary toxicity of immune checkpoint immunotherapy10.1172/JCI170503 ↗
12. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study10.2147/IJN.S186344 ↗
13. Immunomodulatory r848-loaded anti-pd-l1-conjugated reduced graphene oxide quantum dots for photothermal immunotherapy of glioblastoma10.3390/pharmaceutics16081064 ↗
14. Copper-coordination driven nano-frameworks for efficient colorectal cancer chemo-immunotherapy by suppression of cancer cell stemness
15. Mesoporous silicas in materials engineering: nanodevices for bionanotechnologies
16. Subnanometer local temperature probing and remotely controlled drug release based on azo-functionalized iron oxide nanoparticles10.1021/nl400188q ↗
17. Pore size and porosity dependent zeta potentials of mesoporous silica nanoparticles10.1021/acs.jpcc.0c04602 ↗
18. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy10.1016/j.colsurfb.2020.110824 ↗
19. Mesoporous silica nanoparticles as an ideal platform for cancer immunotherapy: recent advances and future directions10.1002/adhm.202400323 ↗
20. Antibody stabilization for thermally accelerated deep immunostaining10.1038/s41592-022-01569-1 ↗
21. Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy10.7150/thno.38989 ↗
22. Intratumor heterogeneity: the rosetta stone of therapy resistance10.1016/j.ccell.2020.03.007 ↗
23. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution10.1016/j.ccell.2014.12.001 ↗
24. Releasing the brakes of tumor immunity with anti-pd-l1 and pushing its accelerator with l19-il2 cures poorly immunogenic tumors when combined with radiotherapy10.1136/jitc-2020-001764 ↗
25. Mitochondria-targeted multifunctional nanoparticles combine cuproptosis and programmed cell death-1 downregulation for cancer immunotherapy
26. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment10.1186/s12943-019-0974-6 ↗
27. Global characterization of t cells in non-small-cell lung cancer by single-cell sequencing10.1038/s41591-018-0045-3 ↗
28. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity10.1126/sciadv.abc3646 ↗
29. Beyond cancer cells: targeting the tumor microenvironment with gene therapy and armed oncolytic virus10.1016/j.ymthe.2021.04.015 ↗
30. Metabolic interactions in the tumor microenvironment10.1016/j.tcb.2017.06.003 ↗
31. Histone lactylation bridges metabolic reprogramming and epigenetic rewiring in driving carcinogenesis: oncometabolite fuels oncogenic transcription10.1002/ctm2.1614 ↗
32. Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation
33. Stem-like exhausted and memory cd8(+) t cells in cancer10.1038/s41568-023-00615-0 ↗
34. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell rna sequencing10.1186/s13073-023-01164-9 ↗
35. On the dependency of cellular protein levels on mrna abundance10.1016/j.cell.2016.03.014 ↗
36. Proteogenomics connects somatic mutations to signalling in breast cancer10.1038/nature18003 ↗
37. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses10.1038/nrg3185 ↗
38. Mast cells in the tumor microenvironment10.1007/978-3-030-49270-0_9 ↗
39. Focus on mast cells in the tumor microenvironment: current knowledge and future directions
40. Macrophages in immunoregulation and therapeutics10.1038/s41392-023-01452-1 ↗
41. Cd206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity10.1172/jci.insight.155022 ↗
42. Perspective on direction of control: cellular metabolism and macrophage polarization10.3389/fimmu.2022.918747 ↗
43. Developmental relationships of four exhausted cd8(+) t cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms10.1016/j.immuni.2020.04.014 ↗
44. Subsets of exhausted cd8(+) t cells differentially mediate tumor control and respond to checkpoint blockade10.1038/s41590-019-0312-6 ↗